ketamine

ketamine

Introduction

What comes to mind when you think of Ketamine? A drug of abuse? A horse tranquiliser? An anaesthetic agent? In reality it is all three. It usually has short-term hallucinogenic effects or causes a dissociative feeling (e.g. detachment from reality, sedation, or  inability to move). However, with frequent use over time it can cause permanent problems such as ‘ketamine bladder’, resulting in pain and difficulty passing urine.

What we already know

 

Ketamine’s effects are mainly mediated via NMDA (N-methyl-D-aspartate) receptor antagonism, although it is also an agonist at some opioid receptors and interacts with various other receptors, including noradrenaline, serotonin and muscarinic cholinergic receptors.

It is a class B illicit substance and was, in fact, upgraded from class C in June 2014 following a review of its harmful effects. Ketamine (either intramuscularly or intravenously) is licensed for use as an anaesthetic agent in children, young people and adults, but over the last few years interest has been growing in the role of Ketamine as an antidepressant agent. It is not currently licensed for this purpose.

Areas of uncertainty

A study published in 2013 suggested that a single injected dose of Ketamine was associated with a rapid-onset antidepressant effect in patients with treatment-resistant depression (Murrough et al). The biggest challenge in terms of research with ketamine is that it remains tricky to compare against a placebo, given the fairly obvious side effects of taking a hallucinogenic drug, but this study compared Ketamine with Midazolam and this is probably the best comparator so far.

The following year, an open label study was published, which found similar antidepressant effects but a whole host of adverse effects were identified (Diamond et al), including anxiety and panic symptoms, increased suicidal ideation, vomiting, headaches and the anticipated feelings of detachment, confusion and dissociative symptoms.

There was a paucity of good quality information until, in 2015, a systematic review and meta-analysis of 21 studies  showed that single ketamine infusions produced a significant anti-depressant effect for up to seven days. Beyond this time, there was no evidence to suggest a prolonged effect.

What’s in the pipeline

There is some evidence to suggest that Ketamine may also work for Post-Traumatic Stress Disorder and Obsessive Compulsive Disorder. Another proposed use for Ketamine (currently being researched at the University of Manchester) is as an adjunct for Electroconvulsive Therapy (ECT), potentially minimizing the cognitive impairments experienced post-ECT.

Ketamine remains one of the most promising new treatments for depression, both unipolar and bipolar, but it is not without its problems. Requiring specialist referral and a stay in hospital overnight for a single dose clearly has financial and logistical implications far beyond those of antidepressant tablets with a stronger evidence base behind them. We also need more information about safety and adverse effects, before it can be introduced to a wider market.

References

Coyle, C. M. and Laws, K. R. (2015), The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum. Psychopharmacol Clin Exp. [Abstract]

Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, Geddes JR and McShane R. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic (PDF). J Psychopharmacol, 0269881114527361, first published on April 3, 2014. [PDF]

Murrough, J.W.; Iosifescu, D.V.; Chang, L.C.; Al Jurdi, R.K.; Green, C.E.; Perez, A.M. et al. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression; a two-site randomized controlled trial. Am J Psychiatry, 170, 1134-1142. [Abstract]

Acknowledgement

Written by: Josephine Neale
Reviewed by: Helge HasselmannAlex Langford 
Last updated: Sep 2015
Review due: Sep 2016

Our ketamine Blogs

New and emerging treatments for major depressive disorder

Sprouts of hope for treatment resistant depression?

Kirsten Lawson summarises a new ‘state of the art review’ in the BMJ which focuses on novel and emerging pharmacotherapy and neuromodulation for people with ‘treatment resistant depression’.

[read the full story...]

Using the highs to combat the lows: ketamine-assisted therapy for anxiety and depression

ketamine

In her debut blog, Gabrielle Williams reviews a US study on the safety and effectiveness of ketamine-assisted therapy (a digital intervention combining psychotherapy, journaling and ketamine) for moderate to severe anxiety and depression.

[read the full story...]

Ketamine and suicidal ideation: French trial finds modest short-term effects

Ketamine.,Ketamine,Pills,In,Rx,Prescription,Drug,Bottle

Anya Borissova reviews a French trial that claims to be evidence that “ketamine is rapid, safe in the short term, and has persistent benefits for acute care in suicidal patients”.

[read the full story...]

Ketamine “shows promise” as an anti-suicidal ideation agent, but will this promise ever be realised?

sinitta-leunen-aFXiQMUi2zA-unsplash

Rosalind McAlpine and Karel Kieslich summarise a recent systematic review which focuses on the rapid anti-suicidal ideation effect of ketamine.

[read the full story...]

Can ketamine metabolites and gamma power help predict clinical response for ‘treatment resistant depression’?

girl-with-red-hat-r4A-lJTgXQg-unsplash

Anya Borissova summarises a recent randomised placebo-controlled trial that evaluated ketamine metabolites, clinical response, and gamma power for major depression.

[read the full story...]

Patients’ experience of ketamine treatment for depression: the ‘Ketamine and me’ project

shutterstock_562050361

In her debut blog, Harmony Jiang reviews a recent qualitative study exploring patients’ experience and response to ketamine treatment for depression.

[read the full story...]

Intranasal esketamine for treatment-resistant depression: the first clinical study

shutterstock_174166007

Jodi Rintelman writes her debut elf blog on the first randomised controlled trial on the efficacy and safety of intranasal esketamine as an adjunctive treatment to antidepressants for treatment-resistant depression.

[read the full story...]

The antidepressant effects of ketamine are confirmed by a new systematic review and meta-analysis

shutterstock_18453376

Helge Hasselmann summarises a new systematic review and meta-analysis, which confirms the antidepressant effects of ketamine.

[read the full story...]

One new drug a week: club drugs and novel psychoactive substances

shutterstock_36627214

Meg Fluharty summarises a recent report from the Royal College of Psychiatrists and explores why novel psychoactive substances and club drugs need a different response from UK treatment providers.

[read the full story...]

Ketamine for depression: new review highlights the need for an RCT

Helge Hasselmann reviews a new systematic review of ketamine for depression, which highlights the need for an RCT to provide reliable data on the safety, tolerability and best route of administration.

[read the full story...]